Openbookopenbook
Equity
Mymetics Corp(MYMX)
USD --+0.00%
Reward33Low
Risk91High
📊75%Data
Revenue down 74% YoY
MYMX
+0.0 · +0.00%
USD · PINK
Mymetics Corp | Healthcare
Earnings Deterioration
Market Cap:45
ℹ️
Reward Rating
33
Low
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
91
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on MYMX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Mymetics Corp?

Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland.

MYMX · Verdict

Limited reward · high risk

MYMX has limited near-term tailwinds — volatility and cash flow weigh on the model output.

Based on 88% data coverage

MYMX · Verdict

What’s working & what to watch

Watchouts 5

  • Volatility5/100

    Weak vs peers

  • Cash flow6/100

    -28967% free-cash-flow margin

  • Profitability9/100

    -192783% net margin · 0% ROE

  • Balance sheet10/100

    Current ratio 0.01

  • Growth25/100

    Rev -44.4% CAGR · earnings +40.6%

Model-based scoring. For information only — not financial advice.

What is Mymetics Corp?

Mymetics Corporation engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, and malaria. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 45.00.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (33)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap45.00
P/E RatioN/A
Dividend YieldN/A
52 Week High0.0003
52 Week Low0.0003
Last AnnualDecember
IPO Date3/30/1995
IncorporatedUSA
Shares Outstanding152K
No. of Employees2
IndustryBiotechnology
ExchangePINK
Beta2.332
CurrencyUSD · Reports in EUR
Websitewww.mymetics.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.